Opportunities
RSS subscribeExpressions of Interest for Projects Aimed at Immune Intervention Therapies for Type 1 Diabetes
Due: this is perpetual, applications may be submitted at any stage
Organisation: National Health and Medical Research Council
WWW: www.dvdc.org.au/?page=11
description
DVDC (Diabetes Vaccine Development Centre) is a joint initiative of the Australian Government, through the National Health and Medical Research Council (NHMRC) and the Juvenile Diabetes Research Foundation International (JDRF). The University of Melbourne, through the School of Population Health, acts as the Sponsoring Administering Institution for the DVDC.
Following a recent review of its activities, DVDC’s board has broadened the acceptance criteria for projects within its scope. In addition to studies ready for clinical development, DVDC is now also interested in supporting focused, relevant pre-clinical studies. In this context, DVDC seeks to work closely with principal investigators leading such projects to facilitate the translational research required for subsequent early-stage product development.
DVDC’s mission is “to accelerate the development of one or more immunotherapeutic products that will prevent or delay the progress of type 1 diabetes, aiming to have clinical proof of concept in 3–5 years, with the studies conducted to a standard acceptable to an industrial partner”.
DVDC operates as a virtual company to bring together the crucial components of the vaccine/immunotherapeutic development process, up to and including clinical proof-of-concept studies. DVDC funds, supports, and facilitates the activities of groups with different approaches to the development of immunotherapeutic treatments for type 1 diabetes. Although based in Australia and physically located within the University of Melbourne (which acts as its sponsoring administering institution), DVDC seeks to support promising therapeutic candidates worldwide.
DVDC has committed some of its funds to several exciting, leading edge proposals as a result of previous calls for expressions of interest. From its uncommitted funds, DVDC has the ability to support selected new initiatives aimed at the development of new candidate immunotherapeutic products.
DVDC invites submissions of short proposals from organisations worldwide defining their proposed product and outlining their proposed project plan, while explaining how it fits the mission of DVDC and serves the field of Type 1 Diabetes. All information sent to DVDC will be kept strictly confidential.
DVDC reserves the right to remove from further consideration expressions of interest for projects that are too early in development and thus without prospect for defining a specific product candidate. As an indication, to be considered the project needs to revolve around a clearly defined product description and be perceived as no further than two years from having commenced clinical studies. DVDC will consider those projects where some further preclinical studies are required to gather data that are regarded as an essential requirement to progress to the clinic or to the development of a product to “a standard acceptable to an industrial partner”.
DVDC is interested in receiving EoIs from researchers who have serious plans to test a diabetes immunotherapy in the clinic. DVDC can support early stages of testing, including GMP manufacture, small scale fill and finish, and toxicology testing.
Subsequent to initial review, applicants invited to submit a full application will be provided with a written assessment from DVDC’s peer review process and will have an opportunity to respond. DVDC will offer to work collaboratively with principal investigators to facilitate their product development plans and thereby best advance the project to the clinic.
DVDC invites submissions from organisations worldwide.
Whilst all efforts are made to provide you with correct information, we cannot guarantee that the details given here current and accurate. Please click on the WWW link given in order to see the full details.
